Comparação entre lovastatina e o gemfibrozil no tratamento de hiperlipidemias primárias / Comparison between lovastatin and gemfibrozil in treatment of primary hyperlipidemias
Arq. bras. cardiol
;
56(5): 407-412, maio 1991. tab
Artículo
en Portugués
| LILACS
| ID: lil-107861
ABSTRACT
Purpose - To compare the effects of lovastatin and gemfibrozil in patients with primary hyperlipidemias. Patients and Methods - Forty patients with cholesterolemia over 200 mgldl and triglyceridemia not higher than 350 mp/dl, excluded secondary causes, were selected. Twenty patients received lovastatin and 20 gemfibrozil. In order to establish the lipid profile, blood samples were taken after 2 months without medication, after 4 weeks of diet and placebo and after 6 and 12 weeks active treatment. Biochemic profile was determined before and after the treatment with active drug. Results - Thirty nine patients completed the study. Total and LDL-cholesterol were significantly reduced (p < 0.05) by both drugs but lovastatin had greater effect. Only gemfibrozil reduced triglycerides significantly. Neither drug had significant effects on HDL-cholesterol. The tolerance was satisfactory; only one patient (using gemfibrozil) needed to stop the treatment due to gastrointestinal side effects. The biochemic profïle did not present any significant alteration. Conclusion - Both drugs produced useful effects on the lipid profile. Lovastatin produced greater reductions of total and LDL-cholesterol, while gemfibrozil was more active reducing triglycerides. Neither drug changed significantly the HDL-cholesterol
Texto completo:
Disponible
Índice:
LILACS (Américas)
Asunto principal:
Lovastatina
/
Gemfibrozilo
/
Hiperlipidemias
Límite:
Adulto
/
Femenino
/
Humanos
/
Masculino
Idioma:
Portugués
Revista:
Arq. bras. cardiol
Asunto de la revista:
Cardiología
Año:
1991
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS